Pangen
Public · 1 known investors
South Korean biotechnology company developing biosimilars and recombinant proteins produced in CHO cell lines.
Also known as (주)팬젠 · Pangen Biotech Inc. · PanGen Biotech, Inc.
Investors · 1
Company profile
researched Aug 2026PanGen Biotech, Inc. is a South Korean biotechnology company that develops biosimilar and recombinant protein therapeutics. Its disclosed pipeline centers on biosimilars and related biologics, including an epoetin alfa biosimilar targeting the erythropoietin receptor for anemia of chronic renal failure, an aflibercept biosimilar directed at PGF and VEGF-A for macular dystrophy, and a preclinical anti-SFTSV antibody for severe fever with thrombocytopenia syndrome. Drug classes associated with the company span biosimilars, colony-stimulating factors, Fc fusion proteins and antibodies, with therapeutic focus areas recorded in hemic and lymphatic diseases, urogenital diseases and other indications.
The company has sponsored clinical studies in Korea, including a Phase 1 and a multi-national Phase 3 trial of PDA10 (epoetin alfa) versus Eprex in healthy volunteers and in patients with anemia of chronic renal failure, and a Phase 1 study of PGA40 in previously treated patients with severe hemophilia A. Its epoetin alfa biosimilar received first approval in South Korea on 28 November 2019. Company-affiliated researchers have published on high-level production of recombinant human proteins in Chinese hamster ovary (CHO) cells, including activin A, VEGF165, and antibody expression methods.
A registry profile classifies the company under research and development in nanotechnology, lists its head office in Suwon, Gyeonggi-do, and reports 78 employees in 2025, alongside a subsidiary recorded as (주)팬젠.
Traction
The epoetin alfa biosimilar has reached approved status in South Korea (first approval 28 November 2019), while the aflibercept biosimilar and an anti-SFTSV antibody remain at preclinical stage. Three associated clinical trials are recorded as completed. Financial indicators for 2025 show net sales revenue down 8.56% and total operating revenue down 8.62% year over year, with operating profit up 43.22%, EBITDA up 18.44%, net profit up 117.3%, total assets up 7.06% and total equity up 20.14%.
▸Full profile — technology, go-to-market, geography, history
Technology
PanGen Biotech's disclosed technical work centers on recombinant protein expression in Chinese hamster ovary (CHO) cell lines and downstream purification. Published work associated with the company describes isolation of stable CHO cell lines with high expression of recombinant human activin A, producing 0.22 g/L in 11-day fed-batch culture in a 7.5 L bioreactor with purity above 99%, and overexpression of recombinant human VEGF165 at over 80 mg/L in a 7-day batch process. Another publication reports that electroporation of CHO cells in the presence of DMSO increased stable expression of aflibercept and pembrolizumab several-fold and shortened stable cell line development to two to three months, reaching 1.0 g/L for aflibercept and 1.4 g/L for pembrolizumab in simple batch culture without gene amplification.
Go-to-market
As a developer of biosimilar and recombinant protein therapeutics, the company's products address patient populations including those with anemia of chronic renal failure, macular dystrophy, severe hemophilia A, and severe fever with thrombocytopenia syndrome.
Geography
The company is headquartered in South Korea, with a head office address recorded at 4F, 2-Dong, 306, Sinwon-Ro, Yeongtong-gu, Suwon-si, Gyeonggi-do; one profile lists its location as Seoul. Its epoetin alfa biosimilar clinical program included a multi-center, multi-national Phase 3 study, and first regulatory approval was obtained in South Korea.
History
The enterprise was established on 29 January 2010 and is recorded as a public company listed on the Korea Exchange under the ticker 222110. Clinical development of its epoetin alfa biosimilar PDA10 began with a Phase 1 crossover study in healthy male volunteers starting July 2012, followed by a Phase 3 comparative study against Eprex starting October 2013 and approval in South Korea in November 2019. A Phase 1 study of PGA40 in severe hemophilia A patients started in October 2019.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 5
launches, deals, and filingsPanGen Biotech's epoetin alfa biosimilar received its first regulatory approval, in South Korea.
Phase 1, open-label, multi-center study of safety, efficacy and pharmacokinetics of PGA40 in previously treated patients with severe hemophilia A (KCT0006060); recorded as completed.
Multi-center, multi-national, double-blind, randomized, active-controlled parallel-group study of PDA10 (epoetin alfa) compared with Eprex in patients with anemia of chronic renal failure (KCT0006024); recorded as completed.
Randomized, double-blind crossover Phase 1 study evaluating safety and PK/PD of PDA10 (recombinant human epoetin alfa) versus Eprex in healthy male volunteers (KCT0001377); recorded as completed.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 8
primary sources listed
- Home - PanGen Solutionspangensolutions.com · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Pangen do?
- South Korean biotechnology company developing biosimilars and recombinant proteins produced in CHO cell lines.
- Who are Pangen's investors?
- Pangen's investors include Atinum Investment Co. Ltd..